Immunic (IMUX) Q3 2026 Results: Everything Hinges on December MS Data

Immunic reported a third-quarter 2026 GAAP loss of $0.99 per share, missing expectations of $0.95. The shortfall came from higher general and administrative costs, specifically $9.7 million in non-cash stock compensation tied largely to a separation agreement, which pushed G&A to $19.4 million from $6.0 million a year earlier.

Research and development spending also rose, reaching $23.9 million compared with $20.0 million in the same period a year ago. The increase reflected NDA readiness work, drug supply costs, personnel additions, and drug-drug interaction studies as the company moves vidofludimus calcium closer to a regulatory filing. Those increases were partially offset by lower trial-level costs in the ENSURE and CALLIPER studies.

With no product revenue, the entire investment thesis rests on December 2026, when top-line data from the fully enrolled Phase 3 ENSURE-1 (1,121 patients) and ENSURE-2 (1,100 patients) trials in relapsing multiple sclerosis are expected. A positive readout would set up a planned U.S. NDA submission in mid-2027, with approval targeted for 2028. CEO Erik Lundgren described the approaching data window as 'one of the most important periods in its history.'

Immunic ended the quarter with $132 million in cash, a position management says is sufficient to fund operations into late 2027. That runway provides some cushion beyond the December data event, but the company has flagged the need to raise additional capital and noted that weighted-average shares outstanding have already risen to 42.8 million from 19.4 million a year earlier, reflecting the dilution from a February 2026 private placement that built the cash position.

Beyond the ENSURE readout, the company is preparing to enroll the first patient in its Phase 3 PROTECT-MS trial in progressive multiple sclerosis, with that milestone targeted for the first half of 2027. The pipeline also includes the earlier-stage IMU-381 program focused on the Nurr1 platform, though lead candidate identification there is still ongoing. For now, December's data package is the singular near-term event that will determine whether Immunic's commercial build-out has a foundation to stand on.